 data**                                                                                                                                                                                                                                                                                                                            A patient with a progression disease during the treatment by azacitidine. Increasing blast cells in blood and marrow by more than 00% from baseline after 0 cycles of azacytidine therapy.                                                                                                                                                                                          A patient with a progression disease during the treatment by azacitidine. Increasing blast cells in blood and marrow by more than 00% from baseline after 0 cycles of azacytidine therapy.    